MOULTONBOROUGH, NH
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)ADVANCING CANCER TREATMENT, founded in 2018, is a micro nonprofit in the Diseases & Disorders sector that reported $43K in total revenue in fiscal year 2024. Revenue fell 98% from the prior year — a significant decline worth monitoring. Expenses of $824K exceeded revenue, resulting in a 1796% operating deficit.
ACTS MISSION IS TO MAKE THE WASHINGTON, DC METROPOLITAN AREA A LEADER IN ADVANCING CLINICAL TRIAL ACCRUAL, THUS ACCELERATING IMPROVED CANCER CARE AND TREATMENT.
ACTS CURRENT FOCUS IS IMPROVING ACCRUAL TO PROSTATE CANCER CLINICAL TRIALS. ACTS GOAL IS TO CREATE A PROSTATE REGISTRY AIMED AT GETTING A SIGNIFICANT PORTION OF PROSTATE CANCER PATIENTS TO SIGN UP TO...
ACTS CURRENT FOCUS IS IMPROVING ACCRUAL TO PROSTATE CANCER CLINICAL TRIALS. ACTS GOAL IS TO CREATE A PROSTATE REGISTRY AIMED AT GETTING A SIGNIFICANT PORTION OF PROSTATE CANCER PATIENTS TO SIGN UP TO PARTICIPATE BY SUBMITTING A SIMPLE SALIVA TEST THAT WILL PROVIDE THEIR GENETIC INFORMATION FOR RESEARCH, AND PROVIDE AN ALERT SERVICE TO THEM IF ANY TREATMENTS OR THERAPIES MATCH THEIR PROFILE AND COULD HELP CHANGE THEIR OUTCOME.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2024 | 2023 | Change | |
|---|---|---|---|
| Revenue | $43,476 | $2,068,192 | -1.0% |
| Expenses | $824,363 | $1,260,009 | -0.3% |
| Net Income | $-780,887 | $808,183 | -2.0% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| OTIS W BRAWLEY MD | DIRECTOR | 0.20 |
Director
|
$0 | $0 | $0 |
| ROBERT L GROSSMAN | DIRECTOR | 0.20 |
Director
|
$0 | $0 | $0 |
| JEANNY B ARAGON-CHING MD | DIRECTOR | 0.20 |
Director
|
$0 | $0 | $0 |
| DONALD L TRUMP MD | DIRECTOR | 0.20 |
Director
|
$0 | $0 | $0 |
| ADAM R METWALLI MD | DIRECTOR | 0.20 |
Director
|
$0 | $0 | $0 |
| PAMELA BROWN | VICE PRESIDENT, SECRETARY | 0.20 |
Officer
Director
|
$0 | $0 | $0 |
| DAVID BROWN | PRESIDENT, TREASURER | 0.20 |
Officer
Director
|
$0 | $0 | $0 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | $43,476 | $824,363 | $714,351 | $-780,887 |
| 2023 | $2,068,192 | $1,260,009 | $1,484,614 | $808,183 |
| 2022 | $3,010,183 | $3,103,502 | $683,975 | $-93,319 |
| 2021 | $1,500,077 | $819,640 | $1,177,066 | $680,437 |
| 2021 | $1,500,077 | $1,220,509 | $1,176,243 | $279,568 |
| 2020 | $1,600,117 | $1,173,683 | $496,629 | $426,434 |
| 2019 | $604,430 | $534,237 | $70,195 | $70,193 |
Compare ADVANCING CANCER TREATMENT with other nonprofits in New Hampshire and across the country.